CLINICAL EFFECTS OF 12-MONTH THERAPY WITH LOVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE AND DYSLIPIDEMIA
83 patients (46-65 years of age) with stable coronary heart disease (CHD) and dyslipidemia, received standard antiagregant and antianginal therapy, were divided into two groups: the 1st group (n=39) followed hypolipidemic diet and standart therapy; in the 2nd group (n=44) in addition to previously mentioned received lovastatin (20-60 mg/d). The frequency of pectoris were evaluated at baseline and after 12 month-period. The two groups were comparable with respect to baseline characteristics, serum lipids. Results: Treatment with lovastatin brought on the hypolipidemic effect without significant changes of transaminases and side effects. Moreover, there was consistent decreasing of angina pectoris. Conclusion Lipid-lowering therapy improved clinical manifestation of CHD in patients with CHD and dyslipidemia.